Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when GTBP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company faces potential delisting from Nasdaq for failing to maintain minimum $1.00 bid price requirement.
GT Biopharma gets 180-day extension to regain Nasdaq compliance, faces delisting risk
Filed May 22, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
high
Nasdaq granted GT Biopharma until November 16, 2026 to regain compliance with the $1.00 minimum bid price requirement. Stock must close at $1.00+ for 10 consecutive business days to avoid delisting.
Item 3.01 verify on EDGAR → -
high
Company originally fell out of compliance in November 2025 after trading below $1.00 for 30 straight days. The initial 180-day grace period expired May 19, 2026 without regaining compliance.
Item 3.01 verify on EDGAR → -
medium
GT Biopharma qualified for the extension because it meets all other Nasdaq Capital Market listing requirements including market value of publicly held shares, except for the minimum bid price.
Item 3.01 verify on EDGAR → -
high
Company warns there is no assurance it will regain compliance with the minimum bid price requirement or maintain compliance with other Nasdaq listing rules.
Item 3.01 verify on EDGAR →
Summary
GT Biopharma received a critical lifeline from Nasdaq on May 20, 2026, securing an additional 180 days to bring its stock price back above $1.00 per share. The biotech company has been trading below the exchange's minimum bid price since late 2025, and its initial grace period expired without recovery.
The company now has until November 16, 2026 to achieve 10 consecutive trading days with a closing price at or above $1.00, or face delisting from the Nasdaq Capital Market. For retail investors, this is a significant warning sign about the company's financial health and market confidence.
A delisting would force the stock to trade on over-the-counter markets, typically resulting in reduced liquidity, wider bid-ask spreads, and less institutional interest. The company itself acknowledges uncertainty about whether it can regain compliance. Investors should monitor the stock's daily closing prices closely over the coming months. Watch for any announcements about reverse stock splits, which companies often use to artificially boost share prices and regain compliance, though such moves dilute existing shareholders' ownership percentage.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify